Abstract 1679P
Background
CRCI is a recognized long-term sequel following cancer diagnosis and therapy, often understudied in developing countries. Our aim was to estimate the prevalence of CRCI prospectively among our patient population, prior to and following chemotherapy, and its association with different variables.
Methods
120 females with breast cancer stages I-III, aged between 18-65 years were recruited, before receiving chemotherapy. Subjective assessment by the functional assessment of cancer therapy-cognitive function scale (FACT-Cog) and objective by the Montreal cognitive assessment screening test (MOCA) was done at baseline and 3 months into chemotherapy.
Results
All 120 patients completed the baseline assessment, but 11 patients (9%) were lost to follow up. There was a statistically significant decrease in the mean total FACT-Cog score at follow up compared to baseline (mean ± SD: 98.12 ± 25.93 vs 109.4 ± 20.83, p<0.001). On univariate analysis, patients with younger age, premenopausal status and higher level of education significantly reported lower means at both time points. Molecular subtypes showed a significant association with the self-reported scores. Luminal B subtype was significantly associated with the highest reported baseline mean (mean± SD: 117.8 ± 15.38), and hence better self-perceived cognition while triple negative breast cancer (TNBC) was associated with the lowest scores (mean± SD: 97.10 ± 23.91) (p=0.001). Similar results were found at follow up. Only the molecular subtypes were found to significantly affect the self-reported scores, in the multivariate analysis. MOCA showed a negative significant correlation with the FACT-Cog (baseline: r= -0.357, p<0.001, and follow up: r= -0.295, p=0.002).
Conclusions
Self-reported CRCI is reported in our cohort at baseline and worsens following chemotherapy. Age, menopausal status, level of education and molecular subtype showed a significant association with the FACT-Cog score. MOCA might be an insensitive objective test to confirm the self-reported cognitive dysfunction.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1617P - Multi-gene copy number variation risk-score for prediction of survival and therapy response outcome in treatment-naïve metastatic castrate resistant prostate cancer
Presenter: Manish Kohli
Session: Poster session 11
1618P - Clinical prognostic factors within the high volume subgroup of metastatic hormone sensitive prostate cancer (mHSPC) in ENZAMET (ANZUP 1304)
Presenter: Anis Hamid
Session: Poster session 11
1619P - Efficacy of carboplatin in patients with metastatic castration-resistant prostate cancer: Results from the biomarker-driven, randomised, outcome-adaptive ProBio trial
Presenter: Anna Kristiansen
Session: Poster session 11
1620P - Inherited variants in SRD5A genes and response to hormonal therapy in prostate cancer (SWOG S1216)
Presenter: Sue Ingles
Session: Poster session 11
Resources:
Abstract
1621P - Validation of a digital pathology-based multimodal artificial intelligence (MMAI) prostate biopsy biomarker in a prospective, real-world Swedish prostate cancer (PCa) cohort treated with radical prostatectomy
Presenter: Anders Bjartell
Session: Poster session 11
1622P - A phase II study of the first-in-class oral innate immune activator BXCL701 with pembrolizumab in patients with metastatic castration-resistant prostate cancer (mCRPC): Long-term follow-up
Presenter: Rahul Aggarwal
Session: Poster session 11
1623P - Prognostic value of circulating tumour DNA fraction in metastatic castration-resistant prostate cancer: Insights from the ProBio trial
Presenter: Alessio Crippa
Session: Poster session 11
1624P - Total and regional changes in body composition in metastatic hormone-sensitive prostate cancer (mHSPC) patients randomized to receive androgen deprivation + enzalutamide +/- zoledronic acid: The BonEnza study
Presenter: Martina Buffoni
Session: Poster session 11
1625P - Fuzuloparib combined with abiraterone in the neoadjuvant treatment of localised high-risk prostate cancer (FAST-PC): A single-arm phase II study
Presenter: Yao Zhu
Session: Poster session 11